Nurexone Biologic Inc
F:J90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yixin Group Ltd
HKEX:2858
|
CN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
IN |
Nurexone Biologic Inc
Depreciation & Amortization
Nurexone Biologic Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Depreciation & Amortization
$85k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enerflex Ltd
TSX:EFX
|
Depreciation & Amortization
CA$161m
|
CAGR 3-Years
21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
7%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Depreciation & Amortization
CA$144m
|
CAGR 3-Years
56%
|
CAGR 5-Years
49%
|
CAGR 10-Years
31%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Depreciation & Amortization
CA$104.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Depreciation & Amortization
CA$188m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Depreciation & Amortization
$293.9k
|
CAGR 3-Years
16%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Depreciation & Amortization?
Depreciation & Amortization
85k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Depreciation & Amortization amounts to 85k USD.
What is Nurexone Biologic Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 1Y
158%
Over the last year, the Depreciation & Amortization growth was 158%.
